Thu, 08 Sep 2022 08:29:00 -0400
PLAINSBORO, N.J., ( Sept 8 , 2022) – Novo Nordisk today announced the upcoming availability of an unbranded biologic of Tresiba® (insulin degludec) injection, a once-daily long-acting basal insulin indicated to control high blood sugar in patients 1 year of age and older with diabetes. The unbranded biologic, insulin degludec, was approved by the US Food and Drug Administration (FDA) in July 2022 and will be available for prescription-holding patients to order from pharmacies nationwide later this Fall as part of an ongoing effort to expand affordability options for patients in need.
"Unbranded biologics are a part of our ongoing efforts to expand our options for patients who struggle to afford their prescribed insulin, support that is especially crucial for the uninsured and underinsured," said Doug Langa, executive vice president, North America operations and president of Novo Nordisk Inc. "With the addition of this treatment to our portfolio, Novo Nordisk is now able to offer patients unbranded biologic options of both rapid- and long-acting insulins. We recognize that no single solution will work for everyone, and are committed to providing ongoing support to ensure that no patient has to go without insulin because they can’t afford it."
This unbranded biologic of Tresiba® will launch at 65% off of the list price of Tresiba® and will be distributed by Novo Nordisk Pharma, Inc. The list prices will be $118.63 for the U-100 10 ml vial, $177.95 for the U-100 FlexTouch® 5x3 ml, and $213.54 for the U-200 FlexTouch® 3x3 ml.
Affordability Options Available
In addition to the unbranded biologic insulins, Novo Nordisk has several important programs designed to address the accessibility and affordability of the therapies that patients rely on to manage their diabetes, including:
Information about all of Novo Nordisk’s current affordability offerings can be found online at NovoCare.com. More information about insulin degludec and Tresiba® are available by visiting Novo Nordisk Pharma, Inc. (NNPI) and Tresiba.com, respectively.
What is insulin degludec?
Important Safety Information
Do not share your insulin degludec FlexTouch® with other people, even if the needle has been changed. Do not share needles or syringes with another person. You may give other people a serious infection, or get a serious infection from them.
Who should not take insulin degludec?
Do not take insulin degludec if you:
Before taking insulin degludec, tell your health care provider about all your medical conditions, including if you are:
Talk to your health care provider about low blood sugar and how to manage it.
How should I take insulin degludec?
What should I avoid while taking insulin degludec?
What are the possible side effects of insulin degludec?
Insulin degludec may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness.
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.
Please click here for insulin degludec Prescribing Information.
About Unbranded Biologics
The term “unbranded biologic” or “unbranded biological product” generally describes an approved brand name biological product that is marketed without its brand name (proprietary name) on its label. Unbranded biologics are not different in strength, dosage form, route of administration, or presentation compared to the brand name biological product. An unbranded biologic is considered by FDA to be equivalent to its brand name biological product because it is the same product as the brand name biological product.
About Novo Nordisk
Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 95 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity and rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long term and do business in a financially, socially, and environmentally responsible way. With US headquarters in New Jersey and production and research facilities in seven states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk.us, Facebook, Instagram and Twitter.
About Novo Nordisk Pharma Inc. (NNPI):
Novo Nordisk Pharma, Inc. or NNPI is a Novo Nordisk A/S US company. It was formed to bring unbranded biologics of Novo Nordisk branded analog insulins at a reduced list price for people with diabetes who are facing affordability challenges in the US.
Allison Schneider (US)
+ 1 732-513-4875 (mobile)
Tresiba® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22UMA00020 September 2022